文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新型冠状病毒肺炎与小分子治疗药物的前景：是否有值得借鉴的经验？

COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

机构信息

Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.

Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.

出版信息

Pharmacol Res. 2022 May;179:106201. doi: 10.1016/j.phrs.2022.106201. Epub 2022 Apr 1.

DOI:10.1016/j.phrs.2022.106201
PMID:35367622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8970615/
Abstract

The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a standstill. As the disease continues to rage two years on, it is apparent that effective therapeutics are critical for a successful endemic living with COVID-19. A dearth in suitable antivirals has prompted researchers and healthcare professionals to investigate existing and developmental drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some of these drugs initially appeared to be promising for the treatment of COVID-19, they were ultimately found to be ineffective. In this review, we provide a retrospective analysis on the merits and limitations of some of these drugs that were tested against SARS-CoV-2 as well as those used for adjuvant therapy. While many of these drugs are no longer part of our arsenal for the treatment of COVID-19, important lessons can be learnt. The recent inclusion of molnupiravir and Paxlovid™ as treatment options for COVID-19 represent our best hope to date for endemic living with COVID-19. Our viewpoints on these two drugs and their prospects as current and future antiviral agents will also be provided.

摘要

2019 年冠状病毒病（COVID-19）大流行使世界陷入停顿。随着这种疾病持续肆虐两年，显然有效的治疗方法对于成功地与 COVID-19 共存至关重要。缺乏合适的抗病毒药物促使研究人员和医疗保健专业人员研究针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的现有和开发中的药物。尽管其中一些药物最初似乎对治疗 COVID-19 有一定的希望，但最终发现它们无效。在这篇综述中，我们对针对 SARS-CoV-2 以及用于辅助治疗的一些药物的优点和局限性进行了回顾性分析。虽然这些药物中的许多已不再是我们治疗 COVID-19 的武器库的一部分，但仍可以从中吸取重要的经验教训。莫那比拉韦和 Paxlovid™最近被纳入 COVID-19 的治疗选择，这是我们迄今为止对 COVID-19 共存的最佳希望。我们对这两种药物的观点以及它们作为当前和未来抗病毒药物的前景也将提供。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/1cd9c4037523/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/bbb373ff16f1/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/ee2c29aebe72/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/f4fcbab78ce5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/af2a12f20874/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/bd77b79990ab/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/db5cb97eef60/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/a0327e34c31a/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/1cd9c4037523/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/bbb373ff16f1/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/ee2c29aebe72/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/f4fcbab78ce5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/af2a12f20874/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/bd77b79990ab/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/db5cb97eef60/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/a0327e34c31a/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8606/8970615/1cd9c4037523/gr7_lrg.jpg

相似文献

[1]
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?

Pharmacol Res. 2022-5

[2]
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.

Biomed Pharmacother. 2020-8-24

[3]
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.

Pharmacol Res. 2020-5-28

[4]
Contemporary narrative review of treatment options for COVID-19.

Respirology. 2021-8

[5]
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.

Acta Med Indones. 2022-10

[6]
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.

Clin Infect Dis. 2023-1-6

[7]
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.

Arch Pharm (Weinheim). 2022-5

[8]
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).

Pharmacol Res. 2020-5-21

[9]
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.

Curr Med Chem. 2020

[10]
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

J Pharm Sci. 2022-10

引用本文的文献

[1]
Antiviral Effect of Erdosteine in Cells Infected with Human Respiratory Viruses.

Pathogens. 2025-4-15

[2]
The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2.

Proc Natl Acad Sci U S A. 2023-9-26

[3]
The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19.

Viruses. 2023-2-19

[4]
Monkeypox epidemic at the door: should we remain idly by or prepare strongly?

AMB Express. 2023-1-13

[5]
A sustainable synthesis of the SARS-CoV-2 M inhibitor nirmatrelvir, the active ingredient in Paxlovid.

Commun Chem. 2022

[6]
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic.

ACS Omega. 2022-11-13

[7]
Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents.

Front Chem. 2022-10-26

[8]
Glucocorticoids and COVID-19.

Pharmacol Res. 2022-11

[9]
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.

J Biomed Sci. 2022-9-6

[10]
Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.

Microorganisms. 2022-6-24

本文引用的文献

[1]
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2022-1-27

[2]
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Environ Res. 2022-6

[3]
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

Antiviral Res. 2022-2

[4]
Covid-19: WHO recommends baricitinib and sotrovimab to treat patients.

BMJ. 2022-1-13

[5]
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.

N Engl J Med. 2022-1-27

[6]
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.

J Med Virol. 2022-4

[7]
COVID antiviral pills: what scientists still want to know.

Nature. 2021-11

[8]
Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.

BMJ. 2021-11-8

[9]
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.

Nat Commun. 2021-11-5

[10]
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.

Science. 2021-12-24

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索